References
  1. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med . 2015;373(16):1541-1552. doi:10.1056/NEJMra1400972
  2. Peters C, Schrappe M, von Stackelberg A, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol . 2015;33(11):1265-1274. doi:10.1200/JCO.2014.58.9747
  3. Ishaqi MK, Afzal S, Dupuis A, Doyle J, Gassas A. Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia. Bone Marrow Transplant . 2008;41(3):245-252. doi:10.1038/sj.bmt.1705891
  4. Pulsipher M, Peters C, Pui C. High-Risk Pediatric Acute Lymphoblastic Leukemia: To Transplant or Not to Transplant? Biol blood marrow transplant . 2011;17:s137-s148. doi:10.1016/j.bbmt.2010.10.005
  5. Sakellari I, Gavriilaki E, Chatziioannou K, et al. Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study. Ann Hematol . 2018;97(10):1987-1994. doi:10.1007/s00277-018-3383-9
  6. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood . 1977;49(4):511-533.
  7. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant . 2009;15(5):523-536. doi:10.1016/j.bbmt.2008.12.489
  8. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant . 2003;32(6):543-548. doi:10.1038/sj.bmt.1704198
  9. Vassal G, Michel G, Espérou H, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol . 2008;61(1):113-123. doi:10.1007/s00280-007-0455-2
  10. Tse WT, Duerst R, Schneiderman J, Chaudhury S, Jacobsohn D, Kletzel M. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. Bone Marrow Transplant . 2009;44(3):145-156. doi:10.1038/bmt.2008.437
  11. Schechter T, Finkelstein Y, Doyle J, et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant . 2007;13(3):307-314. doi:10.1016/j.bbmt.2006.10.026
  12. Wall DA, Chan KW, Nieder ML, et al. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer . 2010;54(2):291-298. doi:10.1002/pbc.22227
  13. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant . 2002;8(9):468-476. doi:10.1053/bbmt.2002.v8.pm12374451
  14. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation . 1974;18(4):295-304. doi:10.1097/00007890-197410000-00001
  15. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant . 2015;21(3):389-401.e1. doi:10.1016/j.bbmt.2014.12.001
  16. Russell JA, Savoie ML, Balogh A, et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant . 2007;13(7):814-821. doi:10.1016/j.bbmt.2007.03.003
  17. M.L. Savoie, A. Balogh, M.A. Chaudhry, et al. Total body irradiation (TBI) added to fludarabine/busulfan/antithymocyte globulin (FLUBUP/ATG) conditioning increases overall survival and relapse-free survival in patients with acute myeloid leukemia (AML) receiving allogeneic stem cell transplants. Blood . 2006;108 (11):3010. https://doi.org/10.1182/blood.V108.11.3010.3010
  18. Willasch AM, Peters C, Sedláček P, et al. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study [published correction appears in Bone Marrow Transplant. 2021 Oct;56(10):2615]. Bone Marrow Transplant . 2020;55(8):1540-1551. doi:10.1038/s41409-020-0854-0
  19. Peters C, Dalle JH, Locatelli F, et al. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol . 2021;39(4):295-307. doi:10.1200/JCO.20.02529
  20. Chaudhury S, Helenowski I, Duerst R, et al. Reduced toxicity myeloablative conditioning regimen in pediatric hematologic malignancies not associated with improved outcomes. Physicians – Poster Session. Bone Marrow Transplant 52, S124–S516 (2017). https://doi.org/10.1038/bmt.2017.134
  21. Rossoff J, Jacobsohn D, Kwon S, et al. Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. Pediatr Blood Cancer . 2021;68(8):e29087. doi:10.1002/pbc.29087
  22. Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood . 2011;117(25):6963-6970. doi:10.1182/blood-2011-01-332007
  23. Modi D, Singh V, Kim S, et al. Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis. Ann Hematol . 2021;100(4):969-978. doi:10.1007/s00277-021-04445-8
  24. Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant . 2007;13(12):1461-1468. doi:10.1016/j.bbmt.2007.08.006
  25. Amouzegar A, Dey BR, Spitzer TR. Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation. Transfus Med Rev . 2019;33(1):43-50. doi:10.1016/j.tmrv.2018.11.003
  26. Kawahara Y, Morimoto A, Inagaki J, et al. Unrelated cord blood transplantation with myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic factors. Bone Marrow Transplant . 2021;56(2):357-367. doi:10.1038/s41409-020-01019-6
  27. Konuma T, Kanda J, Yamasaki S, et al. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. Transplant Cell Ther . 2021;27(4):334.e1-334.e11. doi:10.1016/j.jtct.2021.01.023
  28. Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med . 2017;377(22):2167-2179. doi:10.1056/NEJMra1609337
  29. Dalle JH, Balduzzi A, Bader P, et al. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes. Biol Blood Marrow Transplant . 2018;24(9):1848-1855. doi:10.1016/j.bbmt.2018.05.009.
  30. Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA. Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplant . 2019;54(7):1094-1106. doi:10.1038/s41409-018-0393-0
  31. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood . 2001;98(10):2942-2947. doi:10.1182/blood.v98.10.2942
  32. Silcock R, Mitchell K, Fraser C, Clark J. Epidemiology and outcome for viremia in children undergoing bone marrow transplant: A retrospective cohort study. Transpl Infect Dis . 2021;23(4):e13580. doi:10.1111/tid.13580
  33. Tsoumakas K, Giamaiou K, Goussetis E, et al. Epidemiology of viral infections among children undergoing hematopoietic stem cell transplant: Α prospective single-center study. Transpl Infect Dis . 2019;21(4):e13095. doi:10.1111/tid.13095
  34. Rustia E, Violago L, Jin Z, et al. Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant . 2016;22(9):1646-1653. doi:10.1016/j.bbmt.2016.05.014
  35. Rowe RG, Guo D, Lee M, Margossian S, London WB, Lehmann L. Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center. Biol Blood Marrow Transplant . 2016;22(7):1275-1283. doi:10.1016/j.bbmt.2016.04.004
  36. Alexandersson A, Koskenvuo M, Tiderman A, et al. Viral infections and immune reconstitution interaction after pediatric allogenic hematopoietic stem cell transplantation. Infect Dis (Lond) . 2019;51(10):772-778. doi:10.1080/23744235.2019.1650198
  37. Castagnola E, Bagnasco F, Faraci M, et al. Incidence of bacteremias and invasive mycoses in children undergoing allogeneic hematopoietic stem cell transplantation: a single center experience. Bone Marrow Transplant . 2008;41(4):339-347. doi:10.1038/sj.bmt.1705921
  38. Heston SM, Young RR, Hong H, et al. Microbiology of Bloodstream Infections in Children After Hematopoietic Stem Cell Transplantation: A Single-Center Experience Over Two Decades (1997-2017). Open Forum Infect Dis . 2020;7(11):ofaa465. Published 2020 Sep 30. doi:10.1093/ofid/ofaa465
  39. Goussetis E, Efstathiou E, Paisiou A, et al. Infectious complications following allogeneic stem cell transplantation by using anti-thymocyte globulin-based myeloablative conditioning regimens in children with hemoglobinopathies. Transpl Infect Dis . 2015;17(2):201-207. doi:10.1111/tid.12358
  40. Zając-Spychała O, Wachowiak J, Pieczonka A, et al. Bacterial infections in pediatric hematopoietic stem cell transplantation recipients: incidence, epidemiology, and spectrum of pathogens: report of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation. Transpl Infect Dis . 2016;18(5):690-698. doi:10.1111/tid.12581.
  41. Jahan D, Peile E, Sheikh MA, et al. Is it time to reconsider prophylactic antimicrobial use for hematopoietic stem cell transplantation? a narrative review of antimicrobials in stem cell transplantation. Expert Rev Anti Infect Ther . 2021;19(10):1259-1280. doi:10.1080/14787210.2021.1902304
  42. Bartelink IH, van Reij EM, Gerhardt CE, et al. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant . 2014;20(3):345-353. doi:10.1016/j.bbmt.2013.11.027
  43. Law J, Cowan MJ, Dvorak CC, et al. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biol Blood Marrow Transplant . 2012;18(11):1656-1663. doi:10.1016/j.bbmt.2012.05.006
  44. Boztug H, Zecca M, Sykora KW, et al. Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Ann Hematol . 2015;94(2):297-306. doi:10.1007/s00277-014-2196-8
  45. Pasquini MC, Le-Rademacher J, Zhu X, et al. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant . 2016;22(8):1424-1430. doi:10.1016/j.bbmt.2016.04.013
  46. Kebriaei P, Bassett R, Lyons G, et al. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant . 2017;23(2):285-292. doi:10.1016/j.bbmt.2016.11.001
  47. Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol . 2000;18(2):340-347. doi:10.1200/JCO.2000.18.2.340
  48. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med . 2012;367(16):1487-1496. doi:10.1056/NEJMoa1203517
  49. Dupuis LL, Najdova M, Saunders EF. Retrospective appraisal of busulfan dose adjustment in children [published correction appears in Bone Marrow Transplant. 2003 Apr;31(8):729]. Bone Marrow Transplant . 2000;26(11):1143-1147. doi:10.1038/sj.bmt.1702700
  50. Pulsipher MA, Langholz B, Wall DA, et al. Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?. Bone Marrow Transplant . 2015;50(9):1173-1179. doi:10.1038/bmt.2015.103
  51. Handgretinger R, Lang P. Could (should) we abandon total body irradiation for conditioning in children with leukemia. Blood Rev . 2022;56:100966. doi:10.1016/j.blre.2022.100966
  52. Langenhorst JB, van Kesteren C, van Maarseveen EM, et al. Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. Blood Adv . 2019;3(14):2179-2187. doi:10.1182/bloodadvances.2018029421.
  53. Dekker L, Calkoen FG, Jiang Y, et al. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Adv . 2022;6(7):1969-1976. doi:10.1182/bloodadvances.2021006700
  54. Rowe RG, Guo D, Lee M, Margossian S, London WB, Lehmann L. Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center. Biol Blood Marrow Transplant . 2016;22(7):1275-1283. doi:10.1016/j.bbmt.2016.04.004